The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Fox News' Bryan Llenas reports from the picket line at Red Hook Terminal in New York on the union's demands and impact of the ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.66 which represents a slight increase of $0.53 or 3.09% from the prior close of $17.13. The stock opened at $17.55 and ...

Hims & Hers Health, Inc. HIMS shares rallied 10.1% in the last trading session to close at $19.44. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

The company has been doing incredibly well, and revenue as well as profits have skyrocketed in recent quarters. Shares of ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.77 which represents a slight increase of $0.06 or 0.34% from the prior close of $17.71. The stock opened at ...